Skip to Main Content

Author Details

Rodrigo J Carbajo
Oncology R&D
1997
63
23
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36727211Discovery of a Potent and Orally Bioavailable Zwitterionic Series of Selective Estrogen Receptor Degrader-Antagonists.J Med Chem2023
37186857Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1.Proc Natl Acad Sci U S A2023
35018781Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex.J Chem Inf Model2022
35471939Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS<sup>G12C</sup>.J Med Chem2022
35931745Structure of human spermine oxidase in complex with a highly selective allosteric inhibitor.Commun Biol2022
34913249Relating Conformational Equilibria to Conformer-Specific Lipophilicities: New Opportunities in Drug Discovery.Angew Chem Int Ed Engl2022
34195728Diversity-orientated synthesis of macrocyclic heterocycles using a double S<sub>N</sub>Ar approach.Org Biomol Chem2021
33646774Correction to "Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles".J Med Chem2021
34787423Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-6-mer) Peptides.J Med Chem2021
32910656Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist.J Med Chem2020
32058716Macrocyclic Modalities Combining Peptide Epitopes and Natural Product Fragments.J Am Chem Soc2020
32023060Structure-Based Design and Pharmacokinetic Optimization of Covalent Allosteric Inhibitors of the Mutant GTPase KRAS<sup>G12C</sup>.J Med Chem2020
30640465Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.J Med Chem2019
31206961Observing an Antisense Drug Complex in Intact Human Cells by in-Cell NMR Spectroscopy.Chembiochem2019
31622099Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88<sup>L265P</sup> Mutant Diffuse Large B Cell Lymphoma.J Med Chem2019
31620239Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry.ACS Med Chem Lett2019
31361481Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles.J Med Chem2019
30335946Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6.ACS Chem Biol2018
28714680Correction to Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.J Med Chem2017
28485934Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.J Med Chem2017
24395156Chemical shift assignments and secondary structure of the surrogate domain for drug discovery studies of human heparanase.Biomol NMR Assign2015
26208165In Vivo Detection of Perinatal Brain Metabolite Changes in a Rabbit Model of Intrauterine Growth Restriction (IUGR).PLoS One2015
25363287NMR structure of bitistatin â¿¿ a missing piece in the evolutionary pathway of snake venom disintegrins.FEBS J2015
24413695Dietary gallic acid and anthocyanin cytotoxicity on human fibrosarcoma HT1080 cells. A study on the mode of action.Food Funct2014
25330150Apaf-1 inhibitors protect from unwanted cell death in in vivo models of kidney ischemia and chemotherapy induced ototoxicity.PLoS One2014
23542622Synthesis of fucosyl-N-acetylglucosamine disaccharides by transfucosylation using α-L-fucosidases from Lactobacillus casei.Appl Environ Microbiol2013
24312458Metabolomic profile of umbilical cord blood plasma from early and late intrauterine growth restricted (IUGR) neonates with and without signs of brain vasodilation.PLoS One2013
23989288Progress towards water-soluble triazole-based selective MMP-2 inhibitors.Org Biomol Chem2013
23415087Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.Bioorg Med Chem2013
22569159Novel compounds produced by Streptomyces lydicus NRRL 2433 engineered mutants altered in the biosynthesis of streptolydigin.J Antibiot (Tokyo)2012
22884224Identification of first proadrenomedullin N-terminal 20 peptide (PAMP) modulator by means of virtual screening and NMR interaction experiments.Eur J Med Chem2012
20882536Production of heparanase constructs suitable for nuclear magnetic resonance and drug discovery studies.Biopolymers2011
21552627Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration.Org Biomol Chem2011
21665968Amino acid precursor supply in the biosynthesis of the RNA polymerase inhibitor streptolydigin by Streptomyces lydicus.J Bacteriol2011
21659333Minocycline inhibits cell death and decreases mutant Huntingtin aggregation by targeting Apaf-1.Hum Mol Genet2011
21656569NMR structure and dynamics of recombinant wild type and mutated jerdostatin, a selective inhibitor of integrin α1β1.Proteins2011
21340509Characterization of dequalinium as a XIAP antagonist that targets the BIR2 domain.Apoptosis2011
21398531Biosynthesis of the RNA polymerase inhibitor streptolydigin in Streptomyces lydicus: tailoring modification of 3-methyl-aspartate.J Bacteriol2011
21141810Polymer coiled-coil conjugates: potential for development as a new class of therapeutic "molecular switch".Biomacromolecules2011
20033089The Bronze Age of science in Spain.EMBO Rep2010
21077089Antimicrobial peptides and their superior fluorinated analogues: structure-activity relationships as revealed by NMR spectroscopy and MD calculations.Chembiochem2010
20345344Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery.Curr Med Chem2010
19883706Nanoconjugates as intracorporeal neutralizers of bacterial endotoxins.J Control Release2010
19568652Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles.Chem Commun (Camb)2009
19875077Deciphering biosynthesis of the RNA polymerase inhibitor streptolydigin and generation of glycosylated derivatives.Chem Biol2009
19421720Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors.J Comput Aided Mol Des2009
19352362A kernel for the Tropical Disease Initiative.Nat Biotechnol2009
19381286A kernel for open source drug discovery in tropical diseases.PLoS Negl Trop Dis2009
18076077Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53--a structural and combinatorial approach.Proteins2008
18491984Polymer conjugates as therapeutics: future trends, challenges and opportunities.Expert Opin Drug Deliv2008
  • 1 - 50 of 63

Recommended Authors

Salk Institute for Biological Studies
Career Start Year 2014
Number of shared co-authors 1
Institut de Quimica Avancada de Catalunya (IQAC-CSIC)
Career Start Year 2011
Number of shared co-authors 0
ShanghaiTech University, China iHuman Institute
Career Start Year 2006
Number of shared co-authors 1
Gottfried Schatz Research Center, Medical University of Graz
Career Start Year 2005
Number of shared co-authors 2
Inc. 16 Dekalb Pike
Career Start Year 2002
Number of shared co-authors 0
Dana-Farber Cancer Institute .
Career Start Year 2001
Number of shared co-authors 2
Albert Einstein College of Medicine
Career Start Year 2001
Number of shared co-authors 1
Department of Pharmaceutical Chemistry, University of California San Francisco
Career Start Year 2000
Number of shared co-authors 1
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1999
Number of shared co-authors 3
Lysosomal Therapeutics Inc.
Career Start Year 1997
Number of shared co-authors 3
Swiss Federal Institute of Technology
Career Start Year 1996
Number of shared co-authors 2
University of Bristol
Career Start Year 1996
Number of shared co-authors 2
Institute for Biophysical Chemistry, Goethe-University
Career Start Year 1995
Number of shared co-authors 1
Kangwon National University College of Medicine
Career Start Year 1993
Number of shared co-authors 1
Bridge Institute, University of Southern California
Career Start Year 1991
Number of shared co-authors 0
Institute of Microbiology of the CAS
Career Start Year 1991
Number of shared co-authors 1
University of Toronto
Career Start Year 1989
Number of shared co-authors 3
Heidelberg University
Career Start Year 1989
Number of shared co-authors 0
Leibniz-Forschungsinstitut fur Molekulare Pharmakologie
Career Start Year 1988
Number of shared co-authors 2
iHuman Institute, ShanghaiTech University
Career Start Year 1988
Number of shared co-authors 2
Albert Einstein College of Medicine
Career Start Year 1988
Number of shared co-authors 3
The Francis Crick Institute
Career Start Year 1987
Number of shared co-authors 2
Department of Pharmaceutical Sciences, University of Perugia
Career Start Year 1986
Number of shared co-authors 0
Institute of Systems, The University of Liverpool
Career Start Year 1984
Number of shared co-authors 2
Institute of Pharmaceutical Chemistry, Goethe University
Career Start Year 1983
Number of shared co-authors 2
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Career Start Year 1981
Number of shared co-authors 0
Heartand Lung Research Institute, University of Cambridge
Career Start Year 1971
Number of shared co-authors 1
Albert Einstein College of Medicine
Career Start Year 1969
Number of shared co-authors 1
Institute for Advanced Study, Technical University Munich
Career Start Year 1966
Number of shared co-authors 2
Vanderbilt University
Career Start Year 1954
Number of shared co-authors 2

Collaborators

Instituto de Investigacion Sanitaria La Fe
Co-authored papers 28
Oncology R&D
Co-authored papers 6
Medical Research Council - Laboratory of Molecular Biology
Co-authored papers 5
Oncology R&D
Co-authored papers 5
Principe Felipe Research Center
Co-authored papers 4
Oncology R&D
Co-authored papers 3
University of California San Francisco
Co-authored papers 2
School of Pharmacy, University College London
Co-authored papers 2
From Duke University School of Law
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Co-authored papers 2
Universitat Pompeu Fabra (UPF)
Co-authored papers 2
Oncology R&D
Co-authored papers 2
Co-authored papers 2
University of California at San Francisco
Co-authored papers 2
University of Vermont Cancer Center
Co-authored papers 2
Repare Therapeutics Inc.
Co-authored papers 1
Beth Israel Deaconess Medical Center
Co-authored papers 1